FDA-cleared profile

ClariSIGMAM

ClariPi Inc. · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Calculation of percent breast density and breast-density group information (BI-RADS A+B fatty versus C+D dense) as adjunctive information for interpreting physicians assessing breast tissue composition; not a diagnostic aid.

Clinical role
Automated breast-density measurement and classification as adjunctive information in mammography review; not diagnosis.
Images and patients
Mammography/DBT · Breast tissue, including fibroglandular tissue and total breast area, assessed for each breast.
Key limitation
Keep in mind: The packet limits input to compatible full-field digital mammography systems and for-presentation 2D digital mammograms. Results are adjunctive information and are not a diagnostic aid; no clinical study was required to demonstrate substantial equivalence.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Calculation of percent breast density and breast-density group information (BI-RADS A+B fatty versus C+D dense) as adjunctive information for interpreting physicians assessing breast tissue composition; not a diagnostic aid.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast tissue, including fibroglandular tissue and total breast area, assessed for each breast. Input: For-presentation 2D digital mammograms in RCC, LCC, RMLO, and LMLO views from compatible FFDM systems, including GE Senograph 2000D, GE Senograph DS, GE Senographe Pristina, Hologic Selenia Dimensions, and Hologic Lorad Selenia.
  • Who uses it?Intended users: Interpreting physicians.
  • What does the software produce?Output: For each breast: breast area in cm2, fibroglandular-tissue area in cm2, and percent breast density. For each patient: BI-RADS A+B fatty versus C+D dense group information, displayed on a mammography workstation or PACS as a DICOM mammography Structured Report or secondary capture.
  • What is its most important limitation?Key limitation: The packet limits input to compatible full-field digital mammography systems and for-presentation 2D digital mammograms. Results are adjunctive information and are not a diagnostic aid; no clinical study was required to demonstrate substantial equivalence.

Clinical takeaway. Clinical role: Calculation of percent breast density and breast-density group information (BI-RADS A+B fatty versus C+D dense) as adjunctive information for interpreting physicians assessing breast tissue composition; not a diagnostic aid.

Evidence takeaway. Evidence from the reviewed source record: Non-clinical verification and validation compared ClariSIGMAM density estimates with expert-radiologist reference measurements, assessed reproducibility over time and between breasts, and evaluated binary density classification against a consensus of four expert readers. The reference-standard dataset had n=837; reported endpoints included kappa 0.734 (95% CI 0.688-0.781) and class-specific table percentages of 86.6% for fatty and 87.3% for dense. These are agreement or class-specific classification results, not sensitivity or specificity.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Calculation of percent breast density and breast-density group information (BI-RADS A+B fatty versus C+D dense) as adjunctive information for interpreting physicians assessing breast tissue composition; not a diagnostic aid.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Automated breast-density measurement and classification as adjunctive information in mammography review; not diagnosis.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
For-presentation 2D digital mammograms in RCC, LCC, RMLO, and LMLO views from compatible FFDM systems, including GE Senograph 2000D, GE Senograph DS, GE Senographe Pristina, Hologic Selenia Dimensions, and Hologic Lorad Selenia.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
For each breast: breast area in cm2, fibroglandular-tissue area in cm2, and percent breast density. For each patient: BI-RADS A+B fatty versus C+D dense group information, displayed on a mammography workstation or PACS as a DICOM mammography Structured Report or secondary capture.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Women whose for-presentation 2D digital mammograms come from compatible full field digital mammography systems; the FDA document does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "ClariSIGMAM software is a standalone software application that automatically analyzes “for presentation” 2D digital mammograms to assess breast tissue composition." … "The software assesses the breast density of women and generates a breast density group information for the patient". Read from the exact FDA decision document on 2026-11-14.

Intended users
Interpreting physicians.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
The packet limits input to compatible full-field digital mammography systems and for-presentation 2D digital mammograms. Results are adjunctive information and are not a diagnostic aid; no clinical study was required to demonstrate substantial equivalence.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
Non-clinical verification and validation compared ClariSIGMAM density estimates with expert-radiologist reference measurements, assessed reproducibility over time and between breasts, and evaluated binary density classification against a consensus of four expert readers. The reference-standard dataset had n=837; reported endpoints included kappa 0.734 (95% CI 0.688-0.781) and class-specific table percentages of 86.6% for fatty and 87.3% for dense. These are agreement or class-specific classification results, not sensitivity or specificity.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Non-clinical verification and validation compared ClariSIGMAM density estimates with expert-radiologist reference measurements, assessed reproducibility over time and between breasts, and evaluated binary density classification against a consensus of four expert readers. The reference-standard dataset had n=837; reported endpoints included kappa 0.734 (95% CI 0.688-0.781) and class-specific table percentages of 86.6% for fatty and 87.3% for dense. These are agreement or class-specific classification results, not sensitivity or specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

ClariSIGMAM regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K203785
  • IndependenceIndependence not established

K203785

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K203785. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: For-presentation 2D digital mammograms in RCC, LCC, RMLO, and LMLO views from compatible FFDM systems, including GE Senograph 2000D, GE Senograph DS, GE Senographe Pristina, Hologic Selenia Dimensions, and Hologic Lorad Selenia.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K203785: ClariSIGMAM

  2. Routing

    Source context, not route validation: The device receives digital mammograms using standard DICOM communications and automatically transfers the DICOM summary report to a PACS; output may also be displayed as secondary capture on a mammography workstation. Specific local interface compatibility is not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K203785: ClariSIGMAM

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: For each breast: breast area in cm2, fibroglandular-tissue area in cm2, and percent breast density. For each patient: BI-RADS A+B fatty versus C+D dense group information, displayed on a mammography workstation or PACS as a DICOM mammography Structured Report or secondary capture.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K203785: ClariSIGMAM

  5. Viewer/worklist/report

    Unresolved route: For each breast: breast area in cm2, fibroglandular-tissue area in cm2, and percent breast density. For each patient: BI-RADS A+B fatty versus C+D dense group information, displayed on a mammography workstation or PACS as a DICOM mammography Structured Report or secondary capture.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K203785: ClariSIGMAM

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The device receives digital mammograms using standard DICOM communications and automatically transfers the DICOM summary report to a PACS; output may also be displayed as secondary capture on a mammography workstation. Specific local interface compatibility is not established.
  • Exact FDA submission
  • Checked 2026-09-09

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for ClariSIGMAM; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K203785
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Breast tissue, including fibroglandular tissue and total breast area, assessed for each breast.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-09-10
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K203785 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K203785: ClariSIGMAM

    U.S. Food and Drug Administration - Published 2021-09-10 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ClariSIGMAM model card (K203785)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K203785

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K203785 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K254131

BAC

DeepHealth, Inc.

Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.

Modality
Mammography/DBT
Anatomy
Breast; breast arterial calcifications
Decision
2026-05-21
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history